Pérez-Llorca
We are only able to display limited information for this firm. We display more complete information for all of the following firms:
Pérez-Llorca, which entered the market in July 2025 following its merger with local firm Gómez-Pinzón Abogados, possesses a broad life sciences offering that stands out for its ‘connections with regulatory and oversight bodies’. Forming a key part of the wider regulatory affairs practice, the group assists clients with regulatory filings with authorities, compliance matters, drug pricing strategy, distribution contracts and patent law, among other areas. Senior associate Andrea Pieschacón specialises in health and sanitary regulation and IP law, and is highlighted for her ’availability for critical situations’. Competition, IP and TMT partner Mauricio Jaramillo co-heads the department together with Pieschacón.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- ‘The team stands out for its mastery of the subject, understanding the processes and how to navigate them, and good handling of the necessary technologies.’
- ‘Lawyers demonstrate attention to detail and meticulousness in responses.’
Key clients
- Epizyme Inc.
- Alnylam Pharmaceuticals
Work highlights
Provided regulatory advice to Distrimedical concerning the import of medical devices to Colombia.